Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial

IMPORTANCE: The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high circul...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Bidard, François-Clément, Jacot, William, Kiavue, Nicolas, Dureau, Sylvain, Kadi, Amir, Brain, Etienne, Bachelot, Thomas, Bourgeois, Hugues, Gonçalves, Anthony, Ladoire, Sylvain, Naman, Hervé, Dalenc, Florence, Gligorov, Joseph, Espié, Marc, Emile, George, Ferrero, Jean-Marc, Loirat, Delphine, Frank, Sophie, Cabel, Luc, Diéras, Véronique, Cayrefourcq, Laure, Simondi, Cécile, Berger, Frédérique, Alix-Panabières, Catherine, Pierga, Jean-Yves
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2020
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7645742/
https://ncbi.nlm.nih.gov/pubmed/33151266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.5660
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares